thiazoles has been researched along with inno-406 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (90.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Czyz, M; Jakubowska, J | 1 |
| Cortes, J; Giles, F; Jabbour, E; Kantarjian, H; O'Brien, S | 1 |
| Maekawa, T | 1 |
| Kimura, S | 4 |
| Ashihara, E; Deguchi, Y; Fujiyama, Y; Hodohara, K; Kimura, S; Maekawa, T; Niwa, T | 1 |
| Cortes, J; Quintás-Cardama, A | 1 |
| Müller, BA | 1 |
8 review(s) available for thiazoles and inno-406
| Article | Year |
|---|---|
[Novel inhibitors of Bcr-Abl].
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Mutation; Panobinostat; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyridones; Pyrimidines; Thiazoles | 2006 |
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Topics: Adaptor Proteins, Signal Transducing; Aniline Compounds; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2007 |
[Molecular targeting therapy for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
[Novel anti-CML agents beyond imatinib].
Topics: Adenosine Triphosphate; Aniline Compounds; Antineoplastic Agents; Benzamides; Benzene Derivatives; Binding Sites; Binding, Competitive; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2007 |
Management of patients with resistant or refractory chronic myelogenous leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Treatment Outcome | 2008 |
Imatinib and its successors--how modern chemistry has changed drug development.
Topics: Animals; Antineoplastic Agents; Aurora Kinases; Benzamides; Dasatinib; Drug Discovery; History, 20th Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2009 |
[Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients].
Topics: Aniline Compounds; Antineoplastic Agents; Aurora Kinases; Benzamides; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2009 |
[Development of ABL tyrosine kinase inhibitors].
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2010 |
2 other study(ies) available for thiazoles and inno-406
| Article | Year |
|---|---|
[Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
Topics: Benzamides; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2008 |